Financial Performance - In 2024, the company achieved a revenue of 358.51 million yuan, representing a year-on-year growth of 3.99% [3] - The total profit amounted to 129.74 million yuan, with a year-on-year increase of 1.24% [3] - The net profit attributable to shareholders was 108.87 million yuan, reflecting a growth of 0.73% compared to the previous year [3] Strategic Development - The company aims to strengthen its traditional market competitiveness and implement integrated industrial development while gradually diversifying its business [2] - Future growth will be driven by favorable policy environments, increasing market demand, and ongoing optimization of investment layouts [4] Industry Outlook - The nuclear technology application industry is experiencing rapid expansion, with a growing market for irradiation services in healthcare, pharmaceuticals, and food sectors [4] - The company is positioned to benefit from the increasing demand for high-quality living standards, which will drive the need for irradiation sterilization services [4] Management and Communication - The company emphasizes the importance of shareholder communication and actively responds to investor inquiries [3] - Management has integrated market value management into performance assessment metrics, indicating a commitment to maintaining shareholder confidence [3]

导读： 近日，诺华核药Pluvicto新适应症上市申请获CDE受理，这是该药在中国申报的第二个适应症，2024 年， Pluvicto 销售额达 13.9亿美元，是首个年销售 额破10亿美元的核药。 特别提示 微信机制调整，点击顶部"仪器信息网" → 右上方"…" → 设为 ★ 星标，否则很可能无法看到我们的推送。 近日， 诺华核药Pluv i c t o新适应症上市申请获CDE受理 ，这是该药在中国申报的第二个适应症，此次新适应症若获批，将进一步扩大其覆盖 人群，把治疗线数前移至化疗前阶段。 | 序号 | 受理号 | 药品名称 | 药品类型 | 申请类型 | 注册分类 | 企业名称 | 承力日期 | | --- | --- | --- | --- | --- | --- | --- | --- | | | JXHS2500054 | 撸[177Lu] 特昔维匹肽 | 化药 | 进口 | | Novartis Pharma AG;Advanced Accelerator | 2025-04-28 | | | | | | | | Schweiz | | | | | 注射液 | | | 5.1 | | | | | ...

Industry Overview - The nuclear medicine market is experiencing robust growth due to increasing health awareness and rapid advancements in medical technology [1] - As of July 4, 2024, 88 radioactive new drugs have been approved globally, with only 18 for treatment purposes [1] - From 2021 onwards, China's policies have strongly supported the nuclear medicine industry, which is expected to drive its development [1] - According to Ping An Securities, the nuclear medicine market in China is projected to grow from 5 billion yuan to 26 billion yuan at a CAGR of 26.6% from 2023 to 2030 [1] Company Highlights - Yuan Da Pharmaceutical (00512) is a notable player in the nuclear medicine sector, with a successful Phase II clinical trial for its global innovative product STC3141 [2] - CICC maintains profit forecasts for Yuan Da Pharmaceutical at 2.131 billion yuan for 2025 and 2.235 billion yuan for 2026 [2] - The company has received approval for its innovative drug ITM-11 to conduct Phase III clinical trials, targeting neuroendocrine tumors [3] - China Tongyuan (01763) is a leading enterprise in the nuclear medicine industry, dominating the market for radioactive pharmaceuticals and being the largest supplier of radiation source products in China [4] - In October 2023, China Tongyuan began mass production of a new dual-spiral CT radiation therapy platform, marking a significant advancement in domestic high-end radiation therapy products [4]

以下文章来源于阿基米德Biotech ，作者阿基米德君 阿基米德Biotech . 生物医药第三方独立观察，客观中立，深入浅出，松弛愉悦，写作纯为兴趣，不接广告 超长续航模式。 来源 | 阿基米德Biotech （ID：ArchimedesBiotech） 资本寒冬，一家上市Bi o t e c h也没有挂掉。 1 8A生物科技七年之痒，7 0家公司（含摘B）仍然整整齐齐，一家没少，即使市值最小 的北海康成账上现金仅剩1亿元，但管理层认为2025年有足够的营运资金，即使诺辉健 康复牌暂时没有进展，但离生死大限还有5个月。 中国创新药处于少年时代，（在上市公司层面）有着足够的容错率和包容度，如同《百 年孤独》中初创的"马孔多"，这里全是年轻人，没有死亡，自然没有墓地。 然而，站在中国创新药1 0年节点之上，两大蜕变还是发生了。 今 非 昔 比 ， 《 创 新 药 供 给 侧 改 革 》 （ 2021 年 7 月 ） 指 出 的 内 卷 和 泡 沫 ， 如 今 都 不 再 严 重。 一是行业主要矛盾的蜕变，从同质化竞争的内部矛盾，转为中国生物科技快速崛起与美 国维持生物科技创新领域领导地位之间的外部矛盾。 二是创 ...

Company Overview - As of December 31, 2024, the company has established a network of 37 medical centers and 7 R&D and production bases, serving over 18,000 medical institutions and more than 60 million people annually[10]. - The company employs 3,367 staff as of December 31, 2024, and was listed on the Main Board of the Stock Exchange on July 6, 2018[7]. - The company has a stock code of 1763 and was listed on July 6, 2018[25]. - The company has appointed Ms. Wang Cangren and Ms. Kwan Sau In as joint company secretaries[22]. - The company’s auditor is Shinewing (HK) CPA Limited[22]. - The company has established various committees under the board, including the Audit and Risk Management Committee and the Science and Technology Innovation Committee[21]. Financial Performance - The company achieved an operating income of RMB 7.575 billion, representing a year-on-year increase of 14.2%[30]. - Total profit reached RMB 1.045 billion, reflecting a year-on-year increase of 13.3%[30]. - Net profit was RMB 880 million, also showing a year-on-year increase of 13.3%[30]. - As of December 31, total assets amounted to RMB 14.767 billion, with net assets totaling RMB 7.745 billion[33]. - The gearing ratio stood at 47.56%[33]. - For the year ended December 31, 2024, the company achieved revenue of RMB 7,574.8 million, representing a year-on-year increase of 14.2%[110]. - The net profit for the same period was RMB 879.5 million, reflecting a year-on-year increase of 13.3%, with net profit attributable to the parent company reaching RMB 406.6 million, up 9.6% year-on-year[110]. - The gross profit margin decreased to 48.6% from 52.5% in the previous year, while the operating profit margin slightly improved to 14.3%[106]. Market Position and Products - The company supplies over 40,000 sets of ancillary radioactive source equipment and has captured nearly 70% of the large-scale Class A radiotherapy equipment market in China, making it the leading brand in this category[10]. - CIRC is the largest manufacturer of imaging diagnostic and therapeutic radiopharmaceuticals in China, and the only service provider covering the entire process of irradiation stations[8]. - The company launched the sodium fluorine-18 injection, the first PET imaging agent approved for bone imaging in China, filling a market gap[114]. - The therapeutic sodium iodine-131 capsule's negotiated price was officially implemented, meeting more clinical needs[114]. - The Group's nuclear medical equipment and related services generated RMB1,223.0 million in revenue, marking a year-on-year growth of 31.0%[129]. Research and Development - In 2024, the company achieved a significant milestone with the completion of the first domestic production line for carrier-free lutetium-177 with an annual output of 10,000 curies and a production capacity of thousands of germanium-gallium generators, marking the capability for large-scale commercial production of these nuclides in China[35][36]. - The annual R&D investment reached RMB 660 million, representing a year-on-year increase of 3.3%, with an investment intensity of 8.6%[35][36]. - The company was granted 224 new patent authorizations in 2024, including 65 invention patents[35][43]. - The R&D team consists of 507 personnel focused on optimizing production technologies and developing new products, contributing to technological innovation across various industrial fields[165]. Strategic Initiatives - The company aims to enhance its core functions and competitiveness, focusing on the "6+N" industrial layout, which includes nuclides, nuclear medicines, and irradiation applications[11]. - The company is committed to providing integrated solutions for nuclear medicine and radiotherapy, contributing to the development of a "strong nuclear power nation" and a "healthy China"[7]. - The company is implementing the "Healthy China" strategy to enhance core functions and competitiveness[33]. - The company aims to stabilize growth, strengthen innovation, and promote reform in the nuclear healthcare sector[33]. - The Group aims to support the "Healthy China" strategy by providing integrated solutions for nuclear medicine and radiotherapy, enhancing healthcare delivery across the country[181]. International Expansion - The company won the bid for a million-curie gamma irradiation station project in Bangladesh, marking its first breakthrough in overseas government agency EPC projects[36][41]. - The Group successfully signed the irradiation station project of Bangladesh Nuclear Agricultural Research Institute in 2024, marking the first overseas government agency irradiation station and the first overseas EPC project[140]. - The overall supply project of nuclear medical equipment in Nigeria was successfully signed, representing the first successful implementation of the Group's overall nuclear medical equipment supply project[140]. - The Group improved its layout in the ASEAN market with the successful export of cold medicine supporting radiopharmaceuticals to Thailand, contributing to new growth in export revenue[140]. Corporate Governance and Changes - The company appointed Mr. Han Yongjiang as the Chairman of the Strategy Committee on September 25, 2024[19]. - The company reported a resignation of Mr. Chen Shoulei from the Audit and Risk Management Committee on June 14, 2024, due to a change in work arrangement[17]. - The company experienced the unfortunate passing of Mr. Tian Jiahe on July 21, 2024, due to illness[19]. - The company reported the resignation of Ms. Liu Xiuhong from the Remuneration and Appraisal Committee on March 28, 2025, due to a change in work arrangement[18]. Social Responsibility and Community Engagement - Over 700 public welfare activities were conducted during the reporting period, demonstrating the company's commitment to social responsibility[114]. - The Group is committed to enhancing nuclear medicine's role in diagnosing and treating major diseases, contributing to the "Healthy China" initiative[200]. - The Group's focus on quality has resulted in multiple national awards for quality control groups and trustworthy teams[197]. Technological Advancements - The company has entered the high-end radiotherapy equipment market in collaboration with U.S. Accuray, focusing on advanced technologies such as spiral tomography systems and radiosurgery robots[8]. - The world's first spiral tomotherapy system, Tomo C, was officially completed and delivered from CNNC Accuray's Tianjin plant on June 25, 2024[49]. - The Precision treatment planning system for the Tomo C was approved by the National Medical Products Administration on June 5, 2024, providing a comprehensive treatment planning solution[62]. - The Group's digital transformation initiatives include real-time data collection and analysis of key equipment, aimed at optimizing operational processes[167]. Industry Trends and Future Outlook - By 2023, the direct economic output value of China's nuclear technology application industry was approximately RMB240 billion, with an industry scale of about RMB540 billion, maintaining a growth rate of 15% to 20% for several consecutive years[102][104]. - The Three-Year Action Plan for the High-Quality Development of Nuclear Technology Application Industry (2024-2026) aims for the annual direct economic output value to reach RMB400 billion by 2026, indicating strong future growth prospects[102][104]. - The nuclear technology application industry aligns with national strategies such as Healthy China and is supported by various government initiatives aimed at enhancing public health and medical technology[100][101].

Investment Rating - The report maintains an "Outperform" rating for the pharmaceutical sector [1]. Core Insights - The commercialization of nuclear medicine is accelerating, with significant growth in diagnostic nuclear drugs and the potential for domestic nuclear drugs to reach a commercialization inflection point [3][17]. - The report highlights the successful commercialization of Pluvicto and Lutathera, which are expected to generate substantial revenues, with Pluvicto projected to exceed $5 billion in peak sales [3][12]. - The report emphasizes the similarities between Radioligand Therapy (RDC) and Antibody-Drug Conjugates (ADC), suggesting that RDC could replicate the success of ADC in the market [3][22]. Summary by Sections Part 1: Overseas Nuclear Drug Rapid Growth, Domestic Commercialization Period - Overseas nuclear drugs are experiencing rapid commercialization, with Pluvicto achieving $1.392 billion in revenue in 2024, a 42% increase, and Lutathera generating $724 million, a 20% increase [3][12]. - The combined revenue from these two drugs for Novartis reached $2.116 billion, indicating the ongoing value realization of nuclear drugs [3][12]. - The report notes that the domestic nuclear drug market is set to expand significantly, with five new nuclear drugs approved since 2020, including Yttrium-90 microspheres from Yuan Da Pharmaceutical, which is expected to generate nearly HKD 500 million in revenue in 2024, a growth rate exceeding 140% [3][20]. Part 2: RDC Expected to Replicate ADC Success Path - RDC shares structural and mechanistic similarities with ADC, consisting of a targeting ligand, a linker, and a radioactive nuclide [3][22]. - The report outlines that both RDC and ADC have followed similar validation timelines, with ADC gaining market traction after the success of Enhertu, while RDC is now gaining attention following the success of Pluvicto [3][22]. - The market for new nuclear drugs is projected to reach approximately $4-5 billion in 2024, comparable to the ADC market size around 2021 [3][22]. Part 3: Domestic Nuclear Drug Pipeline Overview - The report details the current pipeline of domestic nuclear drugs, with three products in the NDA stage, including Novartis's PSMA diagnostic and therapeutic drugs [3][49]. - The leading targets in domestic research remain PSMA, FAP, and SSTR, with companies like Yuan Da Pharmaceutical and Xiantong Pharmaceutical leading in clinical project numbers [3][53]. - The anticipated approval of Novartis's two PSMA-targeted products in Q2 2025 is expected to further stimulate the domestic nuclear medicine market [3][20].

Core Viewpoint - China Zhongfu (01763) announced that its subsidiary, China Nuclear High-Tech, signed a capital increase agreement with 404 Chengdu, Chengdu Nuclear General, and Sichuan Tongyuan, raising a total of RMB 2.35 million to enhance the registered capital of Sichuan Tongyuan from RMB 100 million to RMB 123 million [1][2] Group 1 - The capital increase agreement involves 404 Chengdu contributing RMB 12.3457 million and Chengdu Nuclear General contributing RMB 11.1111 million [1] - After the capital increase, China Nuclear High-Tech will hold 81% of Sichuan Tongyuan, while 404 Chengdu and Chengdu Nuclear General will hold 10% and 9%, respectively [1] - Sichuan Tongyuan, established in May 2019, is positioned as a world-class research and production base for radiation sources and is currently in the early stages of project construction and operational layout [1] Group 2 - The funds raised from the capital increase will be used to support the construction and operational funding of the radiation source research and production base project, which will help maintain a reasonable asset-liability structure for Sichuan Tongyuan [1] - The agreement aims to leverage the R&D and production advantages of the shareholders to achieve resource sharing and accelerate the localization of raw materials for radiation sources [2] - This collaboration is expected to create a stable supply chain for raw materials and enhance the industrial synergy among the shareholders, aligning with the overall interests of the company and its stakeholders [2]

Financial Performance - The total revenue for the year ended December 31, 2024, was RMB 7,574,756,000, representing an increase of 14.2% compared to RMB 6,634,992,000 in 2023[4] - Gross profit for the same period was RMB 3,682,832,000, up from RMB 3,482,239,000, indicating a growth of 5.7%[4] - Operating profit increased to RMB 1,086,382,000, a rise of 15.3% from RMB 941,598,000 in the previous year[4] - Net profit for the year was RMB 879,537,000, compared to RMB 776,130,000 in 2023, marking an increase of 13.3%[4] - Basic and diluted earnings per share rose to RMB 1.27 from RMB 1.16, reflecting a growth of 9.5%[4] Assets and Liabilities - Non-current assets increased to RMB 5,849,059,000 from RMB 4,997,241,000, a growth of 17.1%[6] - The company's total assets less current liabilities reached RMB 9,743,980,000, up from RMB 8,937,789,000, indicating an increase of 9.0%[6] - The total equity attributable to shareholders increased to RMB 5,005,301,000 from RMB 4,693,320,000, representing a growth of 6.6%[7] - Trade receivables as of December 31, 2024, totaled RMB 5,155,122,000, an increase of 26.4% from RMB 4,080,997,000 in 2023[30] - Current assets decreased slightly by 1.2% from RMB 3,940.5 million in 2023 to RMB 3,894.9 million in 2024, mainly due to a reduction in cash and an increase in bank loans[98] Revenue Breakdown - The revenue from radiopharmaceutical sales was RMB 4,167,606,000 in 2024, up from RMB 4,017,476,000 in 2023, reflecting a growth of 3.7%[14] - The revenue from nuclear medical equipment sales increased to RMB 912,477,000 in 2024, compared to RMB 706,124,000 in 2023, marking a growth of 29.2%[14] - The group’s revenue from technical services rose to RMB 552,522,000 in 2024, up from RMB 349,390,000 in 2023, representing an increase of 58.2%[14] - The revenue from irradiation services was RMB 172,788,000 in 2024, compared to RMB 161,687,000 in 2023, showing a growth of 6.9%[14] - The group’s revenue from medical device sales increased to RMB 801,650,000 in 2024, up from RMB 544,690,000 in 2023, reflecting a growth of 47.0%[14] Expenses and Costs - Total other income for 2024 was RMB 77,518,000, a significant decrease of 67.8% compared to RMB 240,928,000 in 2023[23] - Total employee costs for 2024 were RMB 886,024,000, up from RMB 867,378,000 in 2023, reflecting a rise of 2.0%[25] - Sales cost rose by 23.4% from RMB 3,152.8 million in 2023 to RMB 3,891.9 million in 2024, primarily due to increased sales costs in nuclear medical equipment and related services[86] - Administrative expenses, R&D costs, and credit impairment losses increased by 3.7% from RMB 1,013.2 million in 2023 to RMB 1,050.3 million in 2024, while the percentage of these costs to revenue decreased from 15.3% to 13.9%[90] - Financial expenses grew by 34.0% from RMB 36.1 million in 2023 to RMB 48.4 million in 2024, primarily due to increased external borrowing for funding needs[91] Dividends and Shareholder Information - The company proposed a final dividend of RMB 0.309 per share for 2024, slightly down from RMB 0.3131 per share in 2023[29] - The expected payment date for the final dividend is before August 2, 2025[131] - Shareholders listed on June 12, 2025, will receive the final dividend for the fiscal year 2024, pending approval at the annual meeting[134] Research and Development - Research and development expenses were RMB 300,286,000, slightly down from RMB 306,051,000 in 2023, showing a decrease of 1.5%[4] - The group applied for 274 patents and obtained 224 patent grants during the reporting period, enhancing its technological capabilities[48] - The company has a talent pool of 507 R&D personnel, including 1 foreign expert, 9 national-level talents, and 11 provincial-level talents, focusing on production technology optimization and new product development[58] Market Expansion and Collaborations - The group is actively expanding its international market presence, participating in various global industry conferences to enhance brand recognition[46] - The company is committed to supporting the "Healthy China" strategy by providing comprehensive solutions for nuclear medicine and radiation therapy[65] - The company is actively pursuing international collaborations and expanding its product offerings in the nuclear medicine sector, including the introduction of new isotopes[42] Corporate Governance and Compliance - The company has complied with the Corporate Governance Code and has established a modern corporate governance framework[124] - The Audit and Risk Management Committee has reviewed the consolidated financial results for the year ending December 31, 2024[126] - The company has not disclosed any significant adverse changes in its financial and operational conditions as of December 31, 2024[111]

88ENNE 中期報告 2024 Interim Report 中國同輻股份有限公司 China Isotope & Radiation Corporation （於中華人民共和國註冊成立的股份有限公司） (A joint stock company incorporated in the People's Republic of China with limited liability) 股份代號 Stock Code：1763 注射用亚缘亚甲基二路B C =7 == 2024 中期報告 Interim Report 目 錄 公司資料 2 財務摘要 4 集團簡介 5 管理層討論與分析 6 企業管治報告及其他資料 32 簡明合併中期財務資料之審閱報告 38 簡明合併損益表 39 簡明合併損益及其他全面收入表 40 簡明合併財務狀況表 41 簡明合併權益變動表 43 簡明合併現金流量表 45 簡明合併中期財務報告附註 46 釋義 69 2 中國同輻股份有限公司 公司資料 | --- | --- | |------------------------------------------------------|- ...

Financial Performance - Revenue for the six months ended June 30, 2024, was RMB 2,810,279 thousand, an increase of 2.6% compared to RMB 2,739,483 thousand for the same period in 2023[2] - Gross profit for the same period was RMB 1,464,150 thousand, slightly down from RMB 1,485,483 thousand, resulting in a gross margin of approximately 52.1%[2] - Operating profit increased to RMB 409,429 thousand, representing a growth of 20.5% from RMB 339,708 thousand in the previous year[2] - Profit for the period attributable to equity shareholders was RMB 154,496 thousand, up 23.2% from RMB 125,413 thousand in the prior year[2] - Basic and diluted earnings per share rose to RMB 0.48, compared to RMB 0.39 for the same period last year, reflecting a 23.1% increase[2] - Total comprehensive income increase of RMB 729,000 for the period, with contributions of RMB 552,000 from equity shareholders and RMB 177,000 from non-controlling interests[12] - Basic and diluted earnings per share increased to RMB 0.400 after accounting policy adjustments, up from RMB 0.398[11] - For the first half of 2024, the company achieved revenue of RMB 2,810.3 million, a year-on-year increase of 2.6%, and a net profit of RMB 306.7 million, up 8.7%[37] Assets and Liabilities - Total assets as of June 30, 2024, amounted to RMB 8,479,589 thousand, an increase from RMB 8,194,469 thousand at the end of 2023[4] - Non-current assets increased to RMB 5,262,997 thousand from RMB 4,997,241 thousand, indicating a growth of 5.3%[4] - Current liabilities rose to RMB 4,414,399 thousand, compared to RMB 4,253,921 thousand at the end of 2023, reflecting an increase of 3.8%[5] - The company reported a net cash position of RMB 2,723,263 thousand, down from RMB 2,891,624 thousand at the end of 2023[4] - The company's trade receivables as of June 30, 2024, amounted to RMB 3,998,300,000, an increase from RMB 3,876,341,000 as of December 31, 2023[32] - The company's cash and cash equivalents as of June 30, 2024, totaled RMB 2,723,263,000, a decrease from RMB 2,891,624,000 as of December 31, 2023[34] Revenue Segments - Pharmaceutical sales generated RMB 1,767,944,000, a slight decrease of 1.1% from RMB 1,787,803,000 in 2023[15] - Revenue from radiation source products increased by 14.7% to RMB 233,247,000, compared to RMB 203,321,000 in 2023[15] - The revenue from the radiation source products segment reached RMB 256.9 million, reflecting a year-on-year growth of 15.0%, driven by increased market demand due to the recovery of the nuclear power industry[41] - The revenue from radiation therapy equipment and related services for the reporting period was RMB 273.8 million, a year-on-year decrease of 31.9% due to delayed certification of the new product Tomo C and reduced sales of older products[44] - The trade services and other businesses generated revenue of RMB 425.2 million, representing a year-on-year increase of 72.8%, primarily driven by the newly acquired industrial testing services and increased sales of isotopes and exported medical equipment[45] Investments and Acquisitions - The company acquired 100% equity of Dalian Nuclear Radiation Technology Co., Ltd. for RMB 4,611,000, making it a subsidiary[9] - As of June 30, 2024, the company has invested RMB 410.4 million in the Tongfu Fund, which has a total paid-in capital of RMB 910.4 million, representing a 45.1% ownership stake[58] - The net assets of the Tongfu Fund, measured at fair value, amount to RMB 1,011.9 million, with the company's share valued at RMB 456.4 million, accounting for 3.3% of the company's total assets[58] - The company plans to utilize the remaining funds from the IPO for various projects, including the establishment of production and distribution subsidiaries and new production facilities[94] Research and Development - The company has launched the first smart nuclear medicine overall solution and the "Radiation Intelligence 1.0" management system, establishing the world's first national-level smart nuclear medicine demonstration center[47] - Multiple radiopharmaceuticals are in various stages of development, including sodium fluoride injection, which has completed clinical trials and submitted for market registration[48] - The group has developed a PET imaging agent, [18F] Florbetazine, for early diagnosis of Alzheimer's disease, which received clinical trial approval on March 8, 2023, and has completed Phase I clinical trials[50] - The group is advancing the development of 6-[18F] Fluoro-L-DOPA for diagnosing Parkinson's disease, with Phase III clinical trials expected to start following its approval on April 17, 2023[50] Market Expansion and Strategy - The company is focused on expanding its market presence and investing in new technologies, although specific figures or timelines were not disclosed in the report[6] - The company plans to continue expanding its product lines and services, particularly in the pharmaceutical and radiation sectors, to drive future growth[16] - The company is actively pursuing international collaborations to introduce advanced radiopharmaceuticals and enhance medical device trade sales[45] - The company aims to achieve a new high in operating revenue and net profit in 2024, driven by favorable policies and a recovering market demand[64] Compliance and Governance - The company has adopted the corporate governance code and has complied with its mandatory provisions during the reporting period[98] - The audit and risk management committee consists of two independent non-executive directors and one non-executive director, ensuring compliance with listing rules[100] - The group has established policies to monitor credit risk and assess the credit quality of new customers before accepting requests exceeding certain credit limits[87] Employee and Operational Metrics - As of June 30, 2024, the company employed 3,132 employees, a decrease from 3,264 employees as of June 30, 2023[95] - Employee costs for the six months ended June 30, 2024, were approximately RMB 378.5 million, compared to RMB 361.0 million for the same period in 2023[95] - The company has a commitment to provide training and development opportunities for employees to enhance their skills and career growth[95]